Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled time : 06:00 save search
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17 (Crawled : 06:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.87%
H: 0.16%
C: -0.59%
kesimpta sclerosis novartis show benefits
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.4%
H: 0.38%
C: -1.77%
lung cancer treatment therapeutics china
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
Published: 2024-02-28 (Crawled : 06:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.6%
H: 0.02%
C: -1.03%
partnership abbvie antibody treatment
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
Published: 2023-12-15 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
first positive treatment ema africa
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
Published: 2023-12-07 (Crawled : 06:00) - globenewswire.com
GNFT | $3.4449 -6.4% 3.5K
|
Health Technology
|
| O: 7.19%
H: 0.0%
C: -6.71%
fda rare drug liver review treatment application grants
Non-Invasive Aesthetic Treatment Market to Reach $37.4 Billion, Globally, by 2032 at 9.2% CAGR: Allied Market Research
Published: 2023-11-28 (Crawled : 06:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -2.99%
H: 0.0%
C: 0.0%
aesthetic reach treatment research market
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
Published: 2023-10-27 (Crawled : 06:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.32%
H: 0.23%
C: -3.06%
nefecon nephropathy drug approval treatment application
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections
Published: 2023-10-19 (Crawled : 06:00) - globenewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.71%
H: 0.0%
C: -2.2%
treatment acquisition antifungal infections
Wastewater Treatment Service Market is to grow by USD 22.62 billion from 2022 to 2027 | The growing demand for reclaimed water to drive the growth- Technavio
Published: 2023-10-18 (Crawled : 06:00) - prnewswire.com
XYL | News | $130.67 -0.04% 0.0% 1.1M
|
Producer Manufacturing
|
| O: -0.78%
H: 0.1%
C: -2.11%
ECL | News | $220.78 0.51% 0.0% 710K
|
Process Industries
|
| O: -1.09%
H: 0.64%
C: -1.35%
AMCR | $9.06 0.89% 0.0% 5.8M
|
Process Industries
|
| O: -0.56%
H: 0.23%
C: -1.59%
water service treatment growing market
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
Published: 2023-09-26 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.39%
H: 0.23%
C: 0.23%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.04%
H: 0.65%
C: -0.31%
dupixent fda children review treatment
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
Published: 2023-09-26 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.39%
H: 0.23%
C: 0.23%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.04%
H: 0.65%
C: -0.31%
dupixent fda children review treatment
Scar Treatment Market size to grow by USD 13.17 billion from 2022-2027 | North America to account for 37% of market growth - Technavio
Published: 2023-09-21 (Crawled : 06:00) - prnewswire.com
BHC | $8.56 0.35% 0.0% 2M
|
Health Technology
|
| O: -1.2%
H: 2.79%
C: 1.82%
america treatment growth market
Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD
Published: 2023-09-11 (Crawled : 06:00) - globenewswire.com
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 0.92%
H: 2.37%
C: -2.17%
fda pharma drug treatment application copd
AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults
Published: 2023-08-17 (Crawled : 06:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.87%
H: 0.49%
C: -0.75%
aquipta abbvie approval treatment migraine
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
Published: 2023-07-24 (Crawled : 06:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
partnership treatment risk hypertension roche cardiovascular
Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
Published: 2023-06-27 (Crawled : 06:00) - globenewswire.com
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 1.55%
H: 0.0%
C: -3.53%
fda pharma drug treatment application copd
EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A
Published: 2023-05-19 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.54%
H: 0.0%
C: 0.0%
CTIC | $9.09 0.05% 11M
|
Health Technology
|
| O: 0.11%
H: 0.11%
C: 0.11%
haemophilia treatment ema application
Water And Wastewater Treatment Chemicals (WWTCs) Market size to grow by USD 18,937.95 million from 2022 to 2027; The increasing demand for freshwater due to the rise in population to drive market growth - Technavio
Published: 2023-05-18 (Crawled : 06:00) - prnewswire.com
ECL | News | $220.78 0.51% 0.0% 710K
|
Process Industries
|
| O: -0.28%
H: 0.61%
C: 0.57%
DOW | $56.98 0.42% 0.0% 5M
|
Process Industries
|
| O: -0.49%
H: 1.51%
C: 1.25%
water treatment growth market
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.